Table 2 Results from the discovery, replication and combined meta-analysis.
From: Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci
Discovery | Replication | Combined | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
CASP+Kiel+WTCCC2+Imm | Exomechip (Utah, Sweden) | Exomechip (Michigan, Toronto, Newfoundland) | PsA GWAS | Genizon GWAS | ||||||
10,262 case+21,871 controls | 913 cases+1,494 controls | 3,168 cases +2,864 controls | 191 cases+356 controls | 761 cases+993 controls | ||||||
Marker | P | Marker | P | Marker | P | Marker | P | Marker | P | P |
rs10789285 | 1.4 × 10−8 | NA | NA | NA | NA | rs720233 | 3.0 × 10−1 | rs720233 | 1.4 × 10−1 | 2.8 × 10−9 |
rs4685408 | 8.6 × 10−9 | rs12497667 | 3.6 × 10−4 | rs12497667 | 1.8 × 10−3 | rs1806555 | 4.4 × 10−1 | rs7653027 | 6.8 × 10−2 | 7.2 × 10−14 |
rs7637230 | 2.1 × 10−9 | rs7637230 | 2.1 × 10−2 | rs7637230 | 6.7 × 10−1 | rs1473857 | 5.5 × 10−2 | rs1473857 | 1.1 × 10−1 | 1.7 × 10−10 |
rs114934997 | 1.3 × 10−8 | rs56054640 | 5.1 × 10−1 | rs56054640 | 1.6 × 10−1 | rs2120854 | 9.3 × 10−1 | rs4957279 | 2.4 × 10−1 | 5.7 × 10−9 |
rs2675662 | 7.4 × 10−9 | rs2675671 | 6.0 × 10−2 | rs2675671 | 2.5 × 10−7 | rs2664282 | 2.0 × 10−1 | rs2675671 | 2.3 × 10−1 | 1.6 × 10−14 |
rs35343117 | 3.1 × 10−8 | rs1483578 | 9.9 × 10−1 | rs1483578 | 8.7 × 10−1 | rs2062234 | 1.3 × 10−3 | rs1483578 | 8.6 × 10−1 | 1.7 × 10−6 |
